143614-45-3

Upstream product

• 143508-53-6 (1S)-1-(4-morpholinomethyl)-5-oxo-5-(phenylmethoxy)phentyl (4S,5R)-4-(cyclohexylmethyl)-2,2-dimethyl-3-<(1,1-dimethylethoxy)carbonyl>-5-oxazolidinecarbxylate 
• 137238-62-1 (4S,5R)-4-Cyclohexylmethyl-2,2-dimethyl-oxazolidine-3,5-dicarboxylic acid 3-tert-butyl ester 5-((S)-4-carboxy-1-morpholin-4-ylmethyl-butyl) ester 
• 137238-59-6 5-Hydroxy-6-morpholin-4-yl-hexanoic acid benzyl ester 
• 137238-61-0 O^ω-<5-<<<(4S,5R)-4-(cyclohexylmethyl)-3-<(1,1-dimethylethoxy)carbonyl>-2,2-dimethyl-5-oxazolidinyl>carbonyl>oxy>-5(S)-(4-morpholinomethyl)pentanoyl>-N^α-<(phenylmethoxy)carbonyl>-L-serine, 1,1-dimethylethyl ester 
• 137238-88-1 4-Oxiranyl-butyric acid benzyl ester 
• 59859-77-7 2-benzyloxycarbonylamino-3-hydroxy-propionic acid tert-butyl ester 

Downstream Products

• 137238-51-8 (3R,4S,7S,14S)-7-Amino-4-cyclohexylmethyl-3-hydroxy-14-morpholin-4-ylmethyl-1,9-dioxa-5-aza-cyclotetradecane-2,6,10-trione 
• 143614-60-2 (2S,9S,12S,13R)-12-(cyclohexylmethyl)-9--L-phenylalanyl>-13-hydroxy-2-(4-morpholinomethyl)-6,10,14-trioxo-1,7-dioxa-11-azacyclotetradecane 

Relevant academic research and scientific papers

Highly Potent, Orally Active Diester Macrocyclic Human Renin Inhibitors

Replacing one amide bond in macrocyclic renin inhibitors of the general structure 1 and 2 with an ester linkage gave glutamate-derived inhibitors 3 and serine-derived inhibitors 4.While this oxygen-for-nitrogen exchange had little effect on potency in the